MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: [Clinical implications of Naples prognostic scores in patients with resectable Siewert type II-III adenocarcinoma of the esophagogastric junction].
Author: Jin P, Ma G, Liu Y, Ke B, Liu HM, Liang H, Zhang RP.
Journal: Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jan 25; 27(1):54-62. PubMed ID: 38262901.
Abstract:
Objective: To evaluate the clinical value of preoperative Naples prognostic scores (NPS) in patients with resectable Siewert type II-III esophagogastric junction adenocarcinoma (AEG). Methods: In this retrospective observational study we collected and analyzed relevant data of patients with Siewert Type II-III AEG treated in the Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital from January 2014 to December 2018. NPS were calculated using preoperative albumin concentration, total cholesterol concentration, neutrophil/lymphocyte ratio, and lymphocyte/monocyte ratio and used to allocate patients into three groups: NTS-0 (0 points), NTS-1 (1-2 points) and NTS-2 (3-4 points). Kaplan-Meier was used to calculate disease-free survival (DFS) and overall survival (OS) in each NPS group and the log-rank test to compare these groups. Univariate and multivariate survival analyes were performed using the Cox regression model. Time-dependent receiver operating characteristic curves were constructed to compare the relationships between four commonly used tools for evaluating inflammatory responses and nutritional status:NPS, systemic inflammatory response scores, nutrient control status (CONUT), and prognostic nutrition index (PNI). Results: The study cohort comprised 221 patients with AEG of median age 63.0 (36.0-87.0) years. There were 190 men (86.0%) and 31 women (14.0%). As to pTNM stage, 47 patients (21.3%) had Stage I disease, 68 (30.8%) Stage II, and 106 (48.0%) Stage III. One hundred and forty-seven patients (66.5%) had Siewert Type II disease and 74 (33.5%) Siewert type III. There were 45 patients (20.4%) in the NPS-0, 142 (64.2%) in the NPS-1 and 34 (15.4%) in the NPS-2 groups. Higher NPS scores were significantly associated with older patients (χ²=5.056, P=0.027) and higher TNM stages (H=5.204,P<0.001). The median follow-up was 39 (6-105) months; 16 patients (7.2%) were lost to follow-up. The median OS in the NPS-0, NPS-1, and NPS-2 groups were 78.4, 63.1, and 37.0 months, respectively; these differences are statistically significant (P=0.021). Univariate and multivariate Cox regression analysis identified the following as independently and significantly associated with OS in patients with Siewert Type II-III: TNM stage (Stage II: HR=2.182, 95%CI: 1.227-3.878, P=0.008; Stage III: HR=3.534, 95%CI: 1.380-6.654, P<0.001), tumor differentiation (G3: HR=1.995, 95%CI: 1.141-3.488, P=0.015), vascular invasion (HR=2.172, 95%CI: 1.403-3.363, P<0.001), adjuvant chemotherapy (HR=0.326, 95%CI: 0.200-0.531, P<0.001), NPS (NPS-1: HR=2.331, 95%CI: 1.371-3.964, P=0.002; NPS-2: HR=2.494, 95%CI: 1.165-5.341, P=0.019), SIS group (NPS-1: HR=2.170, 95%CI: 1.244-3.784, P=0.006; NPS-2: HR=2.291, 95%CI: 1.052-4.986, P=0.037), and CONUT (HR=1.597, 95% CI: 1.187-2.149, P=0.038). The median DFS in the NPS-0, NPS-1, and NPS-2 groups was 68.6, 52.5, and 28.3 months, respectively; these differences are statistically significant (P=0.009). Univariate and multivariate Cox regression analysis identified the following as independently and significantly associated with DFS in patients with Siewert Type II-III AEG: TNM stage (StageⅡ: HR=2.789, 95%CI:1.210-6.428, P=0.016; Stage III: HR=10.721, 95%CI:4.709-24.411, P<0.001), adjuvant chemotherapy (HR=0.640, 95% CI: 0.432-0.946, P=0.025), and NPS (NPS-1: HR=1.703, 95%CI: 1.043-2.782, P=0.033; NPS-2: HR=3.124, 95%CI:1.722-5.666, P<0.001). Time-dependent receiver operating characteristic curves showed that NPS was more accurate in predicting OS and DFS in patients with Siewert Type II-III AEG than were systemic inflammatory response scores, CONUT, or PNI scores. Conclusion: NPS is associated with age and TNM stage, is an independent prognostic factor in patients who have undergone resection of Siewert type II-III AEG, and is better than SIS, CONUT, or PNI in predicting survival. 目的： 探讨那不勒斯预后评分（NPS）在可切除SiewertⅡ~Ⅲ型食管胃结合部腺癌（AEG）治疗前应用的临床价值。 方法： 采用回顾性观察性研究方法，收集2014年1月至2018年12月期间天津医科大学肿瘤医院胃部肿瘤科收治的可切除SiewertⅡ~Ⅲ型AEG患者病例资料等进行回顾性统计分析。根据术前白蛋白浓度、总胆固醇水平、中性粒细胞/淋巴细胞比值、淋巴细胞/单核细胞比值计算NPS，并分为NPS-0（0分）、NPS-1（1和2分）和NPS-2（3和4分）。采用Kaplan-Meier进行不同NPS评分组间无病生存期（DFS）和总生存期（OS）描述，使用log-rank检验进行组间比较，Cox回归模型进行单因素和多因素生存分析，并采用时间依赖性ROC（t-ROC）曲线比较NPS、全身炎性反应评分（SIS）、营养控制状态（CONUT）和预后营养指数（PNI）4个常用的炎性反应-营养评价系统与预后的关系。 结果： 共纳入221例AEG患者，中位年龄63.0（36.0~87.0）岁；男性190例（86.0%），女性31例（14.0%）。根据pTNM分期，Ⅰ期47例（21.3%）、Ⅱ期为68例（30.8%）、Ⅲ期为106例（48.0%）。SiewertⅡ型147例（66.5%）、Ⅲ型74例（33.5%）。NPS-0组45例（20.4%）、NPS-1组142例（64.2%）和NPS-2组34例（15.4%）。NPS评分高与患者年龄偏大（χ²=5.056，P=0.027）和TNM分期偏晚（H=5.204，P<0.001）有关。中位随访39（6~105）个月，16例（7.2%）失访。NPS-0组、NPS-1组与NPS-2组中位OS分别为78.4、63.1和37.0个月，组间比较差异具有统计学意义（P=0.021）。单因素和多因素Cox回归分析显示：影响SiewertⅡ~Ⅲ型AEG患者OS的因素包括TNM分期（Ⅱ期：HR=2.182，95%CI：1.227~3.878，P=0.008；Ⅲ期：HR=3.534，95%CI：1.380~6.654，P<0.001）、肿瘤分化程度（G3：HR=1.995，95%CI：1.141~3.488，P=0.015）、血管侵犯（HR=2.172，95%CI：1.403~3.363，P<0.001）、辅助化疗（HR=0.326，95%CI：0.200~0.531，P<0.001）、PS（NPS-1：HR=2.331，95%CI：1.371~3.964，P=0.002；NPS-2：HR=2.494，95%CI：1.165~5.341，P=0.019）、SIS（NPS-1：HR=2.170，95%CI：1.244~3.784，P=0.006；NPS-2：HR=2.291，95%CI：1.052~4.986，P=0.037）和CONUT（HR=1.597，95%CI：1.187~2.149，P=0.038）。NPS-0组、NPS-1组与NPS-2组间中位DFS分别为68.6、52.5和28.3个月，组间差异也具有统计学意义（P=0.009）。单因素和多因素Cox回归分析显示，影响SiewertⅡ~Ⅲ型AEG患者DFS的因素包括：TNM分期（Ⅱ期：HR=2.789，95%CI：1.210~6.428，P=0.016；Ⅲ期：HR=10.721，95%CI：4.709~24.411，P<0.001）、辅助化疗（HR=0.640，95%CI：0.432~0.946，P=0.025）和NPS（NPS-1：HR=1.703，95%CI：1.043~2.782，P=0.033；NPS-2：HR=3.124，95%CI：1.722~5.666，P<0.001）。t-ROC分析显示：与SIS、CONUT和PNI等评分系统相比，NPS在预测SiewertⅡ~Ⅲ型AEG患者OS及DFS方面均更准确。 结论： NPS与年龄和TNM分期相关，是可切除SiewertⅡ~Ⅲ型AEG的独立预后因素，且在预测生存方面价值优于SIS、CONUT和PNI等评分系统。.

[Abstract] [Full Text] [Related] [New Search]